Patrick Burnett compensation by year
Arcutis Biotherapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $477,267 | $504,203 | $535,000 |
| Bonus | — | $0 | $0 |
| Stock awards | $332,220 | $989,282 | $752,950 |
| Option awards | $611,185 | $709,002 | $1,380,182 |
| Non-equity incentive | $230,878 | $293,274 | $334,376 |
| Pension and deferred compensation | — | $0 | $0 |
| All other | $14,795 | $17,289 | $14,000 |
| Total | $1,666,345 | $2,513,050 | $3,016,508 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 21, 2026, accession 0001787306-26-000028, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 38,000 | $1,103,520 | — |
| RSU | 21,000 | $609,840 | — |
| RSU | 17,000 | $493,680 | — |
| RSU | 11,625 | $337,590 | — |
| RSU | 10,500 | $304,920 | — |
| RSU | 4,450 | $129,228 | — |
| RSU | 4,187 | $121,590 | — |
| RSU | 4,144 | $120,342 | — |
| Option | 80,437 | — | $13.69 |
| Option | 34,937 | — | $13.69 |
| Option | 110,000 | — | $5.58 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2025 proxy (filed April 21, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-19 | Sale | — | 1,697 | $27.00 | 117,592 |
| 2026-08-12 | Exercise or conversion derivative | — | 6,700 | $0.00 | 128,750 |
| 2026-08-12 | Exercise or conversion | — | 6,700 | $3.64 | 125,989 |
| 2026-08-12 | Sale | — | 6,700 | $26.08 | 119,289 |
| 2026-08-11 | Exercise or conversion | — | 8,300 | $3.64 | 127,589 |
| 2026-08-11 | Sale | — | 8,300 | $26.52 | 119,289 |
| 2026-08-11 | Exercise or conversion derivative | — | 8,300 | $0.00 | 135,450 |
| 2026-08-03 | Sale | 10b5-1 | 955 | $26.12 | 119,289 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Arcutis Biotherapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Todd Franklin Watanabe | President and Chief Executive Officer | $7,223,065 |
| L. Todd Edwards | Executive Vice President and Chief Commercial Officer | $3,030,337 |
| Patrick Burnett · this page | Executive Vice President and Chief Medical Officer | $3,016,508 |
| Masaru Matsuda | Executive Vice President, Chief Legal Officer and Corporate Secretary | $2,118,203 |
| David Topper | Former Chief Financial Officer | $1,946,733 |
| Latha Vairavan | Senior Vice President and Chief Financial Officer | $1,924,780 |
The full Arcutis Biotherapeutics compensation record
free company briefThis page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcutis Biotherapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat